



JANET T. MILLS  
GOVERNOR

STATE OF MAINE  
OFFICE OF CANNABIS POLICY  
162 STATE HOUSE STATION  
19 UNION STREET  
FIRST FLOOR  
AUGUSTA, MAINE 04333-0162

ADMINISTRATIVE & FINANCIAL SERVICES

ELAINE CLARK  
ACTING COMMISSIONER

OFFICE OF CANNABIS POLICY

JOHN HUDAK  
DIRECTOR

January 22, 2026

Dear Maine Medical Use of Cannabis Program Participants,

On January 22, 2026, the Office of Cannabis Policy (OCP) issued its first [Medical Cannabis Patient Advisory](#) for contaminated medical cannabis products. Following a patient complaint about an adverse health reaction, OCP conducted an investigation that included testing the concentrate products alleged to have caused the adverse reaction. That testing, along with other testing done on additional cannabis concentrate products, showed varying unsafe levels of multiple pesticides.

While OCP has the authority to issue recalls in the Adult Use Cannabis Program, Maine law does not give OCP that same authority in the Maine Medical Use of Cannabis Program. As such, the Medical Cannabis Patient Advisory issued today aims to make patients aware of five strains of medical cannabis concentrates that were sold at MarijuanaVille and found to contain varying unsafe levels of pesticides. However, because consistent, representative mandatory contaminant testing is not required by the medical cannabis program law, OCP is limited in the amount of information and detail it can provide about the scope of the contamination in MarijuanaVille's cannabis concentrates, especially compared to previous recalls issued in the Adult Use Cannabis Program.

Additionally, the limited inventory recordkeeping requirements in the medical program hinders OCP's ability to identify sources of contamination and/or other registrants who may be in possession of the affected products. OCP continues to investigate this incident and will notify any other registrants directly if they are determined to be impacted. In the meantime, any registrants who suspect they may also be selling the affected products are encouraged to remove those products from their stores and have the products tested for pesticides and other harmful contaminants.

OCP thanks everyone for their attention to this matter. We appreciate your commitment to protecting the health and safety of Maine's medical cannabis patients.

Sincerely,

A handwritten signature in black ink, appearing to read "John Hudak".

John Hudak  
Director